
    
      The secondary objectives of this study are to:

        1. Describe the safety of FluMist and inactivated influenza vaccine.

        2. Describe the incidence and duration of viral replication following immunization with
           FluMist.

        3. To examine the association between immunization response (seroconversion or
           seroprotection) and baseline clinical factors (age, type of malignancy, absolute
           neutrophil count, absolute lymphocyte count, serum IgA, IgG and IgM levels).
    
  